Breaking News Instant updates and real-time market news.

VRX

Valeant

$16.13

-1.0301 (-6.00%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

10:19
11/30/16
11/30
10:19
11/30/16
10:19

Valeant plunges as Salix sale talks said to break down

Shares of Valeant (VRX) are sharply lower in early trading after The Wall Street Journal reported, citing sources, that talks to sell its Salix unit to Japan's Takeda Pharmaceutical (TKPYY) for roughly $10 billion have broken down over price disagreements and other matters. WHAT'S NOTABLE: Valeant is now moving ahead with plans to build the sales force for Salix's Xifaxan, announcing last night that it has initiated a significant sales force expansion to focus on potential primary care physician prescribers of Xifaxan for irritable bowel syndrome with diarrhea, or IBS-D, and Relistor for opioid induced constipation. DEUTSCHE SAID SALE WOULD HAVE BEEN WORTH DOING AT RIGHT PRICE: Weighing on a possible sale of Salix in a note to investors yesterday, Deutsche Bank analyst Gregg Gilbert argued that, on the surface, divesting what could be a "growthy" and durable business is not a no-brainer. However, if Valeant could secure a high enough price to improve its debt burden, he could see why the company would do it, particularly as "maximizing the value of Salix will likely require significant additional resources and management time." Gilbert's early analysis indicates that $10B, plus de-leveraging, would dilute earnings by about 26%-27% in 2018-2021 but boost discounted cash flow value to $32 from $24 and allow Valeant to focus on the durable growth of Bausch + Lomb and its consumer unit. PRICE ACTION: In early trading following the Journal's report, Valeant shares are down 6% to $16.14. Reference Link

VRX

Valeant

$16.13

-1.0301 (-6.00%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

  • 13

    Dec

  • 14

    Dec

  • 16

    Feb

VRX Valeant
$16.13

-1.0301 (-6.00%)

11/18/16
DBAB
11/18/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche still likes near-term setup for Valeant shares
Deutsche Bank analyst Gregg Gilbert said yesterday that he still likes the near-term setup for shares of Valeant Pharmaceuticals after federal prosecutors announced criminal charges against former executive Gary Tanner and the former CEO of Philidor. It is "good to see" that Valeant and other senior executives were not charged, Gilbert told investors in a research note. The charges could be an important step forward as the company and new management team distance themselves from the past, Gilbert wrote. The analyst points out that the bar for 2016 has already been lowered and that new CFO Paul Herendeen thinks of guidance as a commitment. Gilbert keeps a Hold rating on Valeant with a $24 price target. The stock closed yesterday up 12c to $17.98.
11/18/16
ADAM
11/18/16
NO CHANGE
Target $17
ADAM
Hold
Valeant negative headlines remain a risk, says Canaccord
Canaccord analyst Neil Maruoka noted yesterday's headlines regarding criminal charges against a former Valeant executive. He said although the charges are not pertinent to Valeant it underscores the negative headline risk that is associated with owning the shares. Maruoka said the company's lower guidance suggests growth headwinds into next year and believes the company still needs to sell assets to de-lever. Maruoka maintained his Hold rating and $17 price target on Valeant shares.
11/23/16
MZHO
11/23/16
DOWNGRADE
Target $11
MZHO
Underperform
Valeant downgraded to Underperform from Neutral at Mizuho
Mizuho analyst Irina Koffler downgraded Valeant Pharmaceuticals to Underperform, her firm's sell rating equivalent, and cut her price target for the shares to $11 from $25. The drugmaker closed yesterday at $17.83. Koffler believes growth challenges, 2017 guidance risk, legal overhangs and weaker asset divestitures create an unfavorable risk/reward profile. She expects the shares to trend lower over the next 6-12 months.
11/29/16
DBAB
11/29/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche weighs impact on Valeant should Salix be sold
Deutsche Bank analyst Gregg Gilbert hopes to hear closure soon on a potential sale of Salix by Valeant Pharmaceuticals. While a sale is not a "no-brainer" given the unit's growth and durability, a deal could improve Valeant's debt situation and add to its value, Gilbert tells investors in a research note. His preliminary analysis suggests that a sale of Salix for $10B coupled with de-levering would be "significantly" dilutive to earnings but accretive to Valeant's value. His analysis yields earnings dilution of 26%-27% in 2018- 2021 and an increase in the company's theoretical discounted cash flow value to $32 from $24. Gilbert continues to like the near-term setup in shares of Valeant but keeps a Hold rating on the shares with a $24 price target. The pharmaceutical closed yesterday up 44c to $17.44.
TKPYY Takeda Pharmaceutical Co. Ltd.
$20.97

-0.035 (-0.17%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

NOW

ServiceNow

$90.00

-0.24 (-0.27%)

15:20
04/26/17
04/26
15:20
04/26/17
15:20
Options
ServiceNow options imply 10.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 12

    Jun

MS

Morgan Stanley

$44.50

0.225 (0.51%)

15:18
04/26/17
04/26
15:18
04/26/17
15:18
Conference/Events
Morgan Stanley management to meet with Evercore ISI »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

  • 22

    May

TRU

TransUnion

$39.72

0.92 (2.37%)

15:17
04/26/17
04/26
15:17
04/26/17
15:17
Conference/Events
TransUnion management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 09

    May

$NSD

NASDAQ Market Internals

15:17
04/26/17
04/26
15:17
04/26/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRB

H&R Block

$24.07

-0.175 (-0.72%)

, INTU

Intuit

$119.08

0.32 (0.27%)

15:17
04/26/17
04/26
15:17
04/26/17
15:17
Hot Stocks
Trump Effect: Tax preparers fall as administration promises simpler code »

Shares of publicly-traded…

HRB

H&R Block

$24.07

-0.175 (-0.72%)

INTU

Intuit

$119.08

0.32 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZION

Zions Bancorp

$40.49

-1.47 (-3.50%)

15:16
04/26/17
04/26
15:16
04/26/17
15:16
Conference/Events
Zions Bancorp management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

$NYE

NYSE Market Internals

15:16
04/26/17
04/26
15:16
04/26/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$40.34

0.4 (1.00%)

15:14
04/26/17
04/26
15:14
04/26/17
15:14
Hot Stocks
AT&T, IBEW reach tentative agreement in Midwest wireline contract negotiations »

AT&T announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 16

    May

  • 17

    May

ALNY

Alnylam

$51.35

1.05 (2.09%)

, IONS

Ionis Pharmaceuticals

$47.88

2.14 (4.68%)

15:12
04/26/17
04/26
15:12
04/26/17
15:12
Recommendations
Alnylam, Ionis Pharmaceuticals analyst commentary  »

Alnylam data for…

ALNY

Alnylam

$51.35

1.05 (2.09%)

IONS

Ionis Pharmaceuticals

$47.88

2.14 (4.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 09

    May

  • 12

    May

  • 24

    May

  • 06

    Jun

VIX

Volatility Index S&P 500 Options

$10.47

-0.29 (-2.70%)

15:11
04/26/17
04/26
15:11
04/26/17
15:11
Options
Quiet day in the VIX pit as markets see muted reaction to Trump's tax plan »

Quiet day in the VIX pit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STX

Seagate

$50.51

1.09 (2.21%)

15:10
04/26/17
04/26
15:10
04/26/17
15:10
Recommendations
Seagate analyst commentary  »

Needham would be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 08

    Jun

FFIV

F5 Networks

$138.19

0.26 (0.19%)

15:05
04/26/17
04/26
15:05
04/26/17
15:05
Options
F5 Networks options imply 9.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

USB

U.S. Bancorp

$52.47

0.34 (0.65%)

15:01
04/26/17
04/26
15:01
04/26/17
15:01
Hot Stocks
U.S. Bank names Kate Quinn chief administrative officer »

U.S. Bank announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 19

    Jul

  • 18

    Oct

  • 17

    Jan

T

AT&T

$40.26

0.32 (0.80%)

15:00
04/26/17
04/26
15:00
04/26/17
15:00
Hot Stocks
AT&T CEO 'applauds' FCC initiative to remove 'regulatory cloud' over internet »

AT&T Chairman &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 16

    May

  • 17

    May

AMZN

Amazon.com

$907.62

0.21 (0.02%)

14:55
04/26/17
04/26
14:55
04/26/17
14:55
Hot Stocks
Amazon debuts 'Echo Look' camera, style assistant »

Amazon debuted its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 16

    May

  • 16

    May

  • 23

    May

MENB

Mendocino Brewing Company, Inc.

14:52
04/26/17
04/26
14:52
04/26/17
14:52
Hot Stocks
Mendocino Brewing Company gets amendment to current credit facility »

Effective April 25,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$50.95

-0.55 (-1.07%)

14:50
04/26/17
04/26
14:50
04/26/17
14:50
Options
Mellanox options imply 9.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 12

    Jun

TWTR

Twitter

$15.99

1.325 (9.04%)

14:47
04/26/17
04/26
14:47
04/26/17
14:47
Recommendations
Twitter analyst commentary  »

Twitter to be valued like…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ILG

ILG

$23.68

0.57 (2.47%)

14:41
04/26/17
04/26
14:41
04/26/17
14:41
Options
Notable interest in ILG in-the-money calls »

Notable interest in ILG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 25

    May

III

Information Services

$3.19

-0.02 (-0.62%)

14:38
04/26/17
04/26
14:38
04/26/17
14:38
Conference/Events
Information Services management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

COF

Capital One

$83.86

-1.725 (-2.02%)

14:38
04/26/17
04/26
14:38
04/26/17
14:38
Downgrade
Capital One rating change  »

Capital One downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 31

    May

  • 06

    Jun

MCRN

Milacron

$19.17

0.37 (1.97%)

14:37
04/26/17
04/26
14:37
04/26/17
14:37
Hot Stocks
Milacron says DME subsidiary to expand Greenville facility »

Milacron Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 16

    May

  • 16

    May

SAGE

SAGE Therapeutics

$73.37

0.52 (0.71%)

14:36
04/26/17
04/26
14:36
04/26/17
14:36
Options
Sage Therapeutics put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

CB

Chubb

$139.25

2.13 (1.55%)

14:32
04/26/17
04/26
14:32
04/26/17
14:32
Recommendations
Chubb analyst commentary  »

Chubb price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 18

    May

STX

Seagate

$50.51

1.09 (2.21%)

14:26
04/26/17
04/26
14:26
04/26/17
14:26
Recommendations
Seagate analyst commentary  »

Seagate EPS growth should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 08

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.